Ian Todd

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8862236/publications.pdf

Version: 2024-02-01

60	3,487	26	58
papers	citations	h-index	g-index
63	63	63	2994
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The role of CD8 + T lymphocytes in chronic obstructive pulmonary disease: a systematic review. Inflammation Research, 2021, 70, 11-18.	4.0	37
2	Array-based measurements of aero-allergen-specific IgE correlate with skin-prick test reactivity in asthma regardless of specific IgG4 or total IgE measurements. Journal of Immunological Methods, 2021, 492, 112999.	1.4	0
3	Mutations in the binding site of TNFR1 PLAD reduce homologous interactions but can enhance antagonism of wildâ€type TNFR1 activity. Immunology, 2021, 164, 637-654.	4.4	3
4	Multiple pathways of type 1 interferon production in lupus: the case for amlexanox. Rheumatology, 2020, 59, 3980-3982.	1.9	1
5	Electronic cigarette vapour moderately stimulates pro-inflammatory signalling pathways and interleukin-6 production by human monocyte-derived dendritic cells. Archives of Toxicology, 2020, 94, 2097-2112.	4.2	14
6	Extracellular vesicles and asthma: A review of the literature. Clinical and Experimental Allergy, 2020, 50, 291-307.	2.9	26
7	Autoantibodies in chronic obstructive pulmonary disease: A systematic review. Immunology Letters, 2019, 214, 8-15.	2.5	15
8	Cigarette smoking differentially affects immunoglobulin class levels in serum and saliva: An investigation and review. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 474-483.	2.5	35
9	Immunological and pathological effects of electronic cigarettes. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 237-252.	2.5	11
10	Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity. Archives of Dermatological Research, 2019, 311, 141-162.	1.9	17
11	Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics. Respiratory Care, 2018, 63, 609-619.	1.6	45
12	IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review. Archives of Dermatological Research, 2018, 310, 11-28.	1.9	35
13	Positive mood on the day of influenza vaccination predicts vaccine effectiveness: A prospective observational cohort study. Brain, Behavior, and Immunity, 2018, 67, 314-323.	4.1	27
14	Tobacco smoke and nicotine suppress expression of activating signaling molecules in human dendritic cells. Toxicology Letters, 2018, 299, 40-46.	0.8	17
15	Autoantibodies of IgM and IgG classes show differences in recognition of multiple autoantigens in chronic obstructive pulmonary disease. Clinical Immunology, 2017, 183, 344-353.	3.2	9
16	A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing. Pharmacological Research, 2017, 125, 188-200.	7.1	7
17	Peripheral killer cells do not differentiate between asthma patients with or without fixed airway obstruction. Journal of Asthma, 2017, 54, 456-466.	1.7	3
18	Multiple Circulating Cytokines Are Coelevated in Chronic Obstructive Pulmonary Disease. Mediators of Inflammation, 2016, 2016, 1-9.	3.0	26

#	Article	IF	Citations
19	SMAD4 loss enables EGF, $TGF\hat{l}^21$ and $S100A8/A9$ induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cells. Oncotarget, 2016, 7, 69927-69944.	1.8	14
20	Modifying Hofstee standard setting for assessments that vary in difficulty, and to determine boundaries for different levels of achievement. BMC Medical Education, 2016, 16, 34.	2.4	2
21	Tumour necrosis factor receptor I blockade shows that TNFâ€dependent and TNFâ€independent mechanisms synergise in TNF receptor associated periodic syndrome. European Journal of Immunology, 2015, 45, 2937-2944.	2.9	8
22	The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway. Arthritis Research and Therapy, 2015, 17, 93.	3.5	43
23	Development and Validation of Protein Microarray Technology for Simultaneous Inflammatory Mediator Detection in Human Sera. Mediators of Inflammation, 2014, 2014, 1-12.	3.0	26
24	Modifying the Hofstee method may overcome problems. Medical Teacher, 2014, 36, 358-359.	1.8	1
25	A proâ€inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptorâ€associated periodic syndrome (TRAPS). European Journal of Immunology, 2014, 44, 2096-2110.	2.9	36
26	Differential Activation of Killer Cells in the Circulation and the Lung: A Study of Current Smoking Status and Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE, 2013, 8, e58556.	2.5	34
27	Role of interleukinâ€6 in a patient with tumor necrosis factor receptor–associated periodic syndrome: Assessment of outcomes following treatment with the anti–interleukinâ€6 receptor monoclonal antibody tocilizumab. Arthritis and Rheumatism, 2011, 63, 1151-1155.	6.7	90
28	Functional Consequences of Disease-Associated Mutations in TNFR1 Elucidated by Transcriptome Analysis. Advances in Experimental Medicine and Biology, 2011, 691, 461-470.	1.6	1
29	Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. Respiratory Research, 2010, 11, 76.	3.6	52
30	Novel markers of inflammation identified in tumor necrosis factor receptor–associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPSâ€associated tumor necrosis factor receptor type I mutations in an endothelial cell line. Arthritis and Rheumatism, 2009, 60, 269-280.	6.7	27
31	Altered effector function of peripheral cytotoxic cells in COPD. Respiratory Research, 2009, 10, 53.	3.6	42
32	Cell surface expression of TNFRI in tumor necrosis factor receptor–associated periodic syndrome: Comment on the article by Nedjai et al. Arthritis and Rheumatism, 2008, 58, 2213-2214.	6.7	1
33	Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor–associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis and Rheumatism, 2007, 56, 2765-2773.	6.7	45
34	Elevated CD16 expression by monocytes from patients with tumor necrosis factor receptor–associated periodic syndrome. Arthritis and Rheumatism, 2007, 56, 4182-4188.	6.7	21
35	Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor–associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis and Rheumatism, 2006, 54, 2674-2687.	6.7	111
36	Autoantibodies to GAD and IA-2 in Saudi Arabian diabetic patients. Diabetic Medicine, 2005, 22, 448-452.	2.3	34

#	Article	IF	CITATIONS
37	Heterogeneity of tumor necrosis factor receptor-associated periodic syndrome: Comment on the article by Siebert et al. Arthritis and Rheumatism, 2005, 52, 2952-2952.	6.7	3
38	Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatology International, 2005, 25, 183-187.	3.0	38
39	T-Cell-Stimulating Protein A Elicits Immune Responses during Meningococcal Carriage and Human Disease. Infection and Immunity, 2005, 73, 4684-4693.	2.2	7
40	Colorectal Cancer Cells Induce Lymphocyte Apoptosis by an Endothelial Monocyte-Activating Polypeptide-II-Dependent Mechanism. Journal of Immunology, 2004, 172, 274-281.	0.8	32
41	Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology, 2004, 113, 65-79.	4.4	91
42	Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: Differences between cell types. Arthritis and Rheumatism, 2004, 50, 2651-2659.	6.7	73
43	Mapping of Epitopes for Autoantibodies to the Type 1 Diabetes Autoantigen IA-2 by Peptide Phage Display and Molecular Modeling: Overlap of Antibody and T Cell Determinants. Journal of Immunology, 2004, 172, 4084-4090.	0.8	43
44	An immuno-precipitation assay for determining specific interactions between antibodies and phage selected from random peptide expression libraries. Journal of Immunological Methods, 2002, 264, 163-171.	1.4	11
45	Human autologous mixed lymphocyte reaction as anin vitromodel for autoreactivity to apoptotic antigens. Immunology, 2002, 107, 358-365.	4.4	17
46	Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of $65\hat{a} \in fkDa$ glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis. Clinical and Experimental Immunology, 2002, 130, 131-139.	2.6	25
47	Electrical Stimulation of Transforming Growth Factor- \hat{l}^21 Secretion by Human Dermal Fibroblasts and the U937 Human Monocytic Cell Line. ATLA Alternatives To Laboratory Animals, 2001, 29, 693-701.	1.0	17
48	Auto-transporter A protein of Neisseria meningitidis: a potent CD4+ T-cell and B-cell stimulating antigen detected by expression cloning. Molecular Microbiology, 2000, 37, 1094-1105.	2.5	36
49	Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes. Cell, 1999, 97, 133-144.	28.9	1,271
50	Identification and Characterization of TspA, a Major CD4 ⁺ T-Cell- and B-Cell-Stimulating <i>Neisseria</i> -Specific Antigen. Infection and Immunity, 1999, 67, 3533-3541.	2.2	31
51	Ovine trophoblast interferon enhances MHC class I expression by sheep endometrial cells. Journal of Reproductive Immunology, 1998, 37, 117-123.	1.9	12
52	Absence of glutamic acid decarboxylase autoimmunity in symptomatic palatal tremor. Annals of Neurology, 1995, 38, 274-275.	5.3	2
53	On the Issue of Inappropriate HLA Class II Expression on Endocrine Cells: An Answer to a Sceptic. Journal of Autoimmunity, 1995, 8, 313-322.	6.5	8
54	Influence of Tumor Necrosis Factor- \hat{l}_{\pm} on the Modulation by Interferon- \hat{l}_{3} of HLA Class II Molecules in Human Thyroid Cells and Its Effect on Interferon- \hat{l}_{3} Binding*. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 433-439.	3.6	67

#	Article	IF	CITATION
55	Session 7: Tolerance, autoimmunity, and ageing. Developmental and Comparative Immunology, 1989, 13, 417-419.	2.3	0
56	Mechanisms of autoimmunity: Relevance to the pathogenesis of type I (insulinâ€dependent) diabetes mellitus. Diabetes/metabolism Reviews, 1987, 3, 893-923.	0.3	27
57	HLA class II induction in human islet cells by interferon- \hat{l}^3 plus tumour necrosis factor or lymphotoxin. Nature, 1987, 326, 304-306.	27.8	463
58	Organ-Specific Autoimmunity: A 1986 Overview. Immunological Reviews, 1986, 94, 137-169.	6.0	274
59	Immunologic memory to phosphorylcholine. VI. Heterogeneity in light chain gene expression. European Journal of Immunology, 1985, 15, 177-183.	2.9	15
60	COMPARISON OF ANTIGEN-SPECIFIC I-REGION-ASSOCIATED CELL INTERACTION FACTORS. Annals of the New York Academy of Sciences, 1979, 332, 591-604.	3.8	7